

**To:** Goodis, Michael[Goodis.Michael@epa.gov]; Keigwin, Richard[Keigwin.Richard@epa.gov]; Rowland, Jess[Rowland.Jess@epa.gov]; Anderson, Neil[Anderson.Neil@epa.gov]; Cyran, Carissa[Cyran.Carissa@epa.gov]  
**Cc:** Han, Kaythi[Han.Kaythi@epa.gov]  
**From:** Overstreet, Anne  
**Sent:** Mon 3/23/2015 6:03:52 PM  
**Subject:** RE: Glyphosate IARC

I have also received calls from Monsanto and the press is very busy today. We're working to respond to those first then will talk to management about any additional clarifications they would like to make.

---

Anne Overstreet, Chief  
Communication Services Branch  
Field and External Affairs Division  
Office of Pesticide Programs  
Environmental Protection Agency  
overstreet.anne@epa.gov  
(703)308-8068



**From:** Goodis, Michael  
**Sent:** Monday, March 23, 2015 2:03 PM  
**To:** Keigwin, Richard; Rowland, Jess; Anderson, Neil; Cyran, Carissa  
**Cc:** Overstreet, Anne  
**Subject:** Glyphosate IARC

As you can see, I received a call from Dan Jenkins of Monsanto regarding the cancer determinations coming out of the IARC.

Monsanto's position is that the report misrepresents the science and EPA's position and that he talked with Jess and Rick about it and asked whether we would be correcting the record.

I told him that I was not aware of EPA sending out a specific message of “correcting the record,” but that our draft risk assessment would contain the full body of the science.

He sent the attached talking points and other information as an FYI.

Michael L. Goodis, P.E.

Associate Director, Pesticide Re-evaluation Division (7508P)

Office of Pesticide Programs

US Environmental Protection Agency

Phone: 703-308-8157

[goodis.michael@epa.gov](mailto:goodis.michael@epa.gov)

**From:** JENKINS, DANIEL J [AG/1920] [<mailto:daniel.j.jenkins@monsanto.com>]

**Sent:** Monday, March 23, 2015 10:10 AM

**To:** Goodis, Michael

**Cc:** Keigwin, Richard; Cyran, Carissa; Rowland, Jess; Anderson, Neil

**Subject:**

Mike:

Per our phone conversation. We hope EPA will correct mistakes or absences of fact with respect to its record on glyphosate (including the 2013 statement and the AHS study) as it relates to carcinogenicity.

### **2009 EPA Glyphosate Reg Review**

Carcinogenicity was not identified as a concern in the work plan  
[http://www.epa.gov/oppsrrd1/registration\\_review/glyphosate/](http://www.epa.gov/oppsrrd1/registration_review/glyphosate/)

**2013 Federal Register Notice (FR 25396 Vol. 78, No. 84, Wednesday, May 1, 2013) Final Rule** new tolerances in or on multiple commodities: “EPA has concluded that glyphosate does not pose a cancer risk to humans.”

<http://www.gpo.gov/fdsys/pkg/FR-2013-05-01/pdf/2013-10316.pdf>

“For the herbicide **glyphosate**, there was *limited evidence of carcinogenicity* in humans for non-Hodgkin lymphoma. The evidence in humans is from studies of exposures, mostly agricultural, in the USA, Canada, and Sweden published since 2001. In addition, there is convincing evidence that glyphosate also can cause cancer in laboratory animals. On the basis of tumours in mice, the United States Environmental Protection Agency (US EPA) originally classified glyphosate as *possibly carcinogenic to humans* (Group C) in 1985. After a re-evaluation of that mouse study, the US EPA changed its classification to *evidence of non-carcinogenicity in humans* (Group E) in 1991. The US EPA Scientific Advisory Panel noted that the re-evaluated glyphosate results were still significant using two statistical tests recommended in the IARC Preamble. The IARC Working Group that conducted the evaluation considered the significant findings from the US EPA report and several more recent positive results in concluding that there is *sufficient evidence of carcinogenicity* in experimental animals. Glyphosate also caused DNA and chromosomal damage in human cells, although it gave negative results in tests using bacteria. One study in community residents reported increases in blood markers of chromosomal damage (micronuclei) after glyphosate formulations were sprayed nearby.”

[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(15\)70134-8/abstract](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70134-8/abstract)

<http://www.iarc.fr/en/media-centre/iarcnews/pdf/MonographVolume112.pdf>

Thanks,

Dan Jenkins  
U.S. Agency Lead

Regulatory Affairs  
Monsanto Company  
1300 I St., NW  
Suite 450 East  
Washington, DC 20005

Office: 202-383-2851

Cell: 571-732-6575

This e-mail message may contain privileged and/or confidential information, and is intended to be received only by persons entitled to receive such information. If you have received this e-mail in error, please notify the sender immediately. Please delete it and all attachments from any servers, hard drives or any other media. Other use of this e-mail by you is strictly prohibited. All e-mails and attachments sent and received are subject to monitoring, reading and archival by Monsanto, including its subsidiaries. The recipient of this e-mail is solely responsible for checking for the presence of "Viruses" or other "Malware". Monsanto, along with its subsidiaries, accepts no liability for any damage caused by any such code transmitted by or accompanying this e-mail or any attachment. The information contained in this email may be subject to the export control laws and regulations of the United States, potentially including but not limited to the Export Administration Regulations (EAR) and sanctions regulations issued by the U.S. Department of Treasury, Office of Foreign Asset Controls (OFAC). As a recipient of this information you are obligated to comply with all applicable U.S. export laws and regulations.